If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
The album fused together the Reids' two primary influences: the guitar noise of the Stooges and the Velvet Underground with the pop songwriting and melodies of the Beach Boys, The Shangri-Las and Phil Spector; In fact, the album's opening song, "Just Like Honey," borrows Hal Blaine's famous drum intro from The Ronettes 1963 classic, "Be My Baby", produced and co-written by Spector. The record received unanimously positive reviews and is now considered a landmark recording. Drummer Gillespie announced his departure from the band in October 1985, to concentrate on Primal Scream. He had recorded most of the drums on Psychocandy, with John Moore filling in when Gillespie was unavailable, eventually joining the band to replace him. John Loder also acted as a stand-in drummer when Gillespie was unavailable for live performances. When the band signed to Blanco y Negro in January 1985, there were stories reporting that they had stolen money from managing Director Rob Dickens's jacket and destroyed his office, all untrue but seen as good publicity by manager McGee. In a performance on Belgian television in March 1985, the band did smash the set and the audio equipment, but this was at the request of the TV producer. Such behaviour became expected of the band and many shows culminated with the Reids trashing their equipment, which was often followed by the audience throwing projectiles onto the stage and damaging equipment. On 15 March 1985, the Jesus and Mary Chain played a gig at the North London Polytechnic in front of one of their largest crowds up to that point.
=== Impacts === As a pest, the beetle is most damaging to the poultry industry. This is the most common beetle found in poultry litter. The larvae damage poultry housing structures when they search for suitable pupation spots, chewing through wood, fiberglass, and polystyrene insulation. This destruction can be costly to growers, especially in heating energy costs. The beetles consume the birds' feed and irritate the birds by biting them. Other insect residents of poultry housing include the housefly (Musca domestica) and its predator, Carcinops pumilio, a clown beetle. The fly is a pest which can sometimes be kept under control by the beetle. The lesser mealworm interferes with this ecology by reducing the survival of clown beetle eggs and larvae. The lesser mealworm beetle is a vector of many pathogens. It spreads more than 30 bird diseases. It transmits animal viruses such as rotavirus, the turkey coronavirus, the chicken viruses that cause Marek's disease and infectious bursal disease, and the viruses that cause Newcastle disease, avian influenza, and fowlpox. It transmits bacteria such as Campylobacter jejuni, Salmonella enterica serovar Typhimurium, Escherichia coli, and Staphylococcus species. A single exposure of a chick to a contaminated beetle can result in bacterial colonization of the bird's gut. Chicks are more likely to be infected by eating larvae than adult beetles. The beetle can also transmit Aspergillus fungi. It is a vector for Eimeria, protozoa that cause coccidiosis in birds.
2013 The pan-tissue Epigenetic clock is a molecular biomarker by Steve Horvath that facilitates the measurement of the age of all human tissues based on cytosine methylation. 2013 The scientific journal Cell published the article "The Hallmarks of Aging", that was translated to several languages and determined the directions of many studies. 2013 A record for the duration of life among males. Japanese Jiroemon Kimura lived 116 years and 54 days (that is 167 days longer than the previous record). 2013 It was discovered that brain-specific overexpression of Sirtuin 1 (SIRT1) is also capable to extend lifespan and delay aging in mice. 2013 Google and other investors created the company Calico to combat aging and related diseases. Investors provided Calico with more than a billion dollars of funding. Arthur Levinson became CEO of the company and one of its investors. 2014 First evidence that pharmacological activation of SIRT1 extends lifespan in mice and improves their health. 2014 Establishment of the Dog Aging Project at the University of Washington, a decade-long study of aging in dogs which includes clinical trials of rapamycin in some of them to test its effects on lifespan, with the project's ultimate goal being to translate the results into further understanding aging in humans and ways to target it. 2010s second half The emergence of official discussions about the possibility of recognizing aging as a disease.
Sources: en.wikipedia.org
Human genetics have been included within the field of bioethics since the early 1970s and the growth in the use of DNA sequencing (particularly high-throughput sequencing) has introduced a number of ethical issues. One key issue is the ownership of an individual's DNA and the data produced when that DNA is sequenced. Regarding the DNA molecule itself, the leading legal case on this topic, Moore v. Regents of the University of California (1990) ruled that individuals have no property rights to discarded cells or any profits made using these cells (for instance, as a patented cell line). However, individuals have a right to informed consent regarding removal and use of cells. Regarding the data produced through DNA sequencing, Moore gives the individual no rights to the information derived from their DNA. As DNA sequencing becomes more widespread, the storage, security and sharing of genomic data has also become more important. For instance, one concern is that insurers may use an individual's genomic data to modify their quote, depending on the perceived future health of the individual based on their DNA. In May 2008, the Genetic Information Nondiscrimination Act (GINA) was signed in the United States, prohibiting discrimination on the basis of genetic information with respect to health insurance and employment.
Following the nationwide collapse of the Whig Party in 1854, many of Knoxville's Whigs, including Brownlow, were unwilling to support the new Republican Party formed by northern Whigs, and instead aligned themselves with the anti-immigrant American Party (commonly called the "Know Nothings"). When this movement disintegrated, Knoxville's ex-Whigs turned to the Opposition Party. In 1858, Opposition Party candidate Horace Maynard, with Brownlow's endorsement, soundly defeated Democratic candidate J.C. Ramsey (J.G.M. Ramsey's son) for the 2nd district's congressional seat.
The transcription factor p63, which prevents epidermal stem cells from differentiating into keratinocytes. Mutations in the p63 DNA-binding domain are associated with ectrodactyly, ectodermal dysplasia, and cleft lip/palate (EEC) syndrome. The transcriptome of p63 mutant keratinocytes deviated from the normal epidermal cell identity. Vitamin A and its analogues. Epidermal growth factor. Transforming growth factor alpha. Cholera toxin.
=== Electrical properties === Most conventional polymers such as polyethylene are electrical insulators, but the development of polymers containing π-conjugated bonds has led to a wealth of polymer-based semiconductors, such as polythiophenes. This has led to many applications in the field of organic electronics.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.